Active protein or polypeptides derived from human placenta and application of active protein or polypeptides derived from human placenta

A protein and human placenta technology, applied in the field of biomedicine, can solve the problems of no research on active ingredients, and further research on the biological effects of specific proteins and peptides

Pending Publication Date: 2020-05-05
SHINEWAY PHARMA GRP LTD
View PDF7 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In 2013, Hyoung-Joo Lee et al. (Lee HJ et al:Comprehensive Genome-Wide Proteomic Analysis of Human Placental Tissue for the Chromosome-Centric Human Proteome Project. JProteome Res.2013Feb 14) from Yonsei University in South Korea used normal people and pre-eclampsia The patient's placental tissue was used as the research object, and the proteins and polypeptides in human placental tissue were analyzed by proteomics analysis method. As a result, 4239 specific proteins and polypeptides in human placental tissue were identified, and 38 proteins were found Or peptides have the effect of enhancing immune function, but the biological effects of most of the specific proteins and peptides found need to be further studied
However, none of these patents has conducted further research on the active ingredients and their effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Active protein or polypeptides derived from human placenta and application of active protein or polypeptides derived from human placenta
  • Active protein or polypeptides derived from human placenta and application of active protein or polypeptides derived from human placenta
  • Active protein or polypeptides derived from human placenta and application of active protein or polypeptides derived from human placenta

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Example 1. Preparation of anti-hepatitis B placental transfer factor and placental transfer factor

[0094] (1) Pretreatment of human placenta material

[0095] For Anti-HBV Placental Transfer Factor (PSTF) :

[0096] Maternal physical examination standards: maternal serological test, hepatitis B virus surface antibody (HBsAb) positive; hepatitis B virus antigen and antibody HBsAg, HBeAg, HBeAb, HBcAb, hepatitis C virus (HCV), HIV (HIV), Patients with negative results for venereal pathogens (syphilis, gonorrhea, etc.).

[0097] Select the placenta that is positive for hepatitis B virus surface antibody (HBsAb), and negative for hepatitis B virus antigen and antibody (HBsAg, HBeAg, HBeAb, HBcAb), hepatitis C virus (HCV), HIV (HIV), and sexually transmitted disease pathogens . Those who suffer from malignant tumors, immunodeficiency diseases, acute infectious diseases, induced abortions, stillbirths, children with various deformities, abnormal appearance by naked eye...

Embodiment 2

[0115] Embodiment 2. placental transfer factor (PTF) and the immune activity test of anti-hepatitis B placental transfer factor (PSTF)

[0116] 1. Leukocyte Suspension Preparation

[0117] 20ml of peripheral blood from normal people, white blood cells were routinely separated, and the number of white blood cells was adjusted to 5×10 with Hank’s solution 6 pcs / ml, spare.

[0118] 2. HBVM positive serum

[0119] Detect the peripheral blood of HBsAg-positive patients whose HBsAg titer is above 1:512, put it in a sterile test tube, separate the serum routinely, and keep it for later use.

[0120] 3. Experimental method

[0121] 1) PSTF group

[0122] Take 0.5 ml of leukocyte suspension, add 0.5 ml of PSTF injection prepared in Example 1 (protein content greater than 0.5 mg / ml, ribose content greater than 80 μg / ml), and incubate at 37° C. for 30 min to make it sensitized. Remove the supernatant by centrifugation and adjust the number of cells to 5×10 6 pieces / ml.

[0123] Ta...

Embodiment 3

[0134] Example 3. Effect of placental transfer factor (PTF) and anti-hepatitis B placental transfer factor (PSTF) on mouse immune function

[0135] 1. Experimental animals

[0136] Kunming mice weighing between 18-22 g, 30 healthy pups, male and female, were randomly divided into 3 groups.

[0137] 2. Experimental method

[0138] With a frequency of once a day, the mice were injected intraperitoneally with the liquid of placental transfer factor (PTF) and anti-hepatitis B placental transfer factor (PSTF) prepared in Example 1 respectively, and the dose was 0.1ml / kg, carried out 7 times in total ; Use saline as a control.

[0139] On the 8th day of the experiment, the mice were plucked from the eyeballs to get blood, 0.02ml was added to 0.38ml white blood cell diluent, and the number of white blood cells was calculated after mixing; while staining (using Wright's staining method) to test the classification of white blood cells. Then the thymus and spleen of the mice were rem...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to active protein or polypeptides derived from the human placenta and application of the active protein or polypeptides derived from the human placenta. The active protein or polypeptides derived from the human placenta or a combination of the active protein and the polypeptides, compositions of the active protein or the polypeptides or the combination of the active protein and the polypeptides, preparations of the active protein or the polypeptides or the combination of the active protein and the polypeptides, and application of the active protein or the polypeptides orthe combination of the active protein and the polypeptides, the compositions and the preparations are disclosed. By means of the human placenta which is positive for a surface antibody (HBsAb) of Hepatitis B Virus (HBV) and negative for a surface antigen (HBsAg) of the Hepatitis B Virus (HBV), small molecular substances in the human placenta are extracted, and are used to prepare injections, including a liquid injection and a powder injection. According to the invention, a proteomics method is used, the protein or the polypeptides in two kinds of placenta extracts are compared and analyzed, 110 kinds of human placenta active protein or polypeptides with specific immunity are obtained, and experiments prove that the extracts from the placenta which is positive for the surface antibody (HBsAb) of the Hepatitis B virus (HBV) have immunostimulation effects, and have significant therapeutic effects on Hepatitis B.

Description

technical field [0001] The invention relates to the field of biomedicine. Specifically, the present invention relates to a protein or polypeptide or a combination of active proteins or polypeptides, a composition or preparation comprising an active protein or polypeptide or a combination of active proteins or polypeptides, and an active protein or polypeptide having therapeutic or adjuvant treatment of liver disease activity and / or immune enhancing activity. Proteins or polypeptides or active proteins or combinations of polypeptides, compositions or preparations containing active proteins or polypeptides or active proteins or polypeptides are used in preparation for enhancing immune function or treating cancer and / or liver diseases such as (hepatitis B) and other diseases application in medicines. Background technique [0002] The placenta is a transitional organ for the exchange of substances between mother and child formed by the joint growth of the embryonic membrane and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/00A61K38/17A61P1/16A61P37/04
CPCC07K14/00A61P1/16A61P37/04A61K38/00
Inventor 王正品张浩军张涛徐平常蕾李振江
Owner SHINEWAY PHARMA GRP LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap